Jackson, V. E. https://orcid.org/0000-0002-9758-9784
Wu, Y.
Bonelli, R.
Owen, J. P.
Scott, L. W.
Farashi, S.
Kihara, Y.
Gantner, M. L.
Egan, C. https://orcid.org/0000-0001-5593-1169
Williams, K. M. https://orcid.org/0000-0003-4596-3938
Ansell, B. R. E. https://orcid.org/0000-0003-0297-897X
Tufail, A. https://orcid.org/0000-0001-6131-7640
Lee, A. Y. https://orcid.org/0000-0002-7452-1648
Bahlo, M. https://orcid.org/0000-0001-5132-0774
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (APP1195236)
Article History
Received: 9 January 2024
Accepted: 18 December 2024
First Online: 4 February 2025
Competing interests
: A.Y.L. reports grants from Santen, personal fees from Genentech, personal fees from US FDA, personal fees from Johnson and Johnson, personal fees from Boehringer Ingelheim, non-financial support from iCareWorld, grants from Topcon, grants from Carl Zeiss Meditec, personal fees from Gyroscope, non-financial support from Optomed, non-financial support from Heidelberg, non-financial support from Microsoft, grants from Regeneron, grants from Amazon, grants from Meta, outside the submitted work; This article does not reflect the views of the US FDA. A.T. reports no direct funding conflicts with the content of the paper. Other disclosures not directly related to the content of the paper: Allergan; Annexon; Apellis; Bayer; 4DMT; Genetech; Heidelberg Engineering; Iveric Bio; Novartis; Oxurion; Roche; VisionAI. C.Y.E. reports receiving financial support from the UK Department of Health through an award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Biomedical Research Centre for Ophthalmology. C.Y.E. receives consultant fees from Heidelberg Engineering and Inozyme Pharma unrelated to the scope of the current work. No competing interests reported for M.B., J.O., M.L.G., R.B., B.R.E.A., K.W., V.E.J., L.W.S., S.F., Y.K., Y.W.